The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites

Journal of Clinical Gastroenterology

Volumn 40, Issue 4, 2006, Pages 342-346

  Kalambokis, Georgios ^a   Economou, Michalis ^a   Kosta, Paraskevi ^a   Papadimitriou, Konstantinos ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cirrhosis; Diuretics; Octreotide; Portal hypertension

Indexed keywords

DIURETIC AGENT; FUROSEMIDE; OCTREOTIDE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; GLUCAGON BLOOD LEVEL; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; MALE; PLASMA VOLUME; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; ALDOSTERONE; ASCITES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; GASTROINTESTINAL AGENTS; HEMODYNAMIC PROCESSES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OCTREOTIDE; PORTAL SYSTEM; PORTAL VEIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; ULTRASONOGRAPHY, DOPPLER;

EID: 33748136809     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000210101.74618.61     Document Type: Article

References (38)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis: I. Portal hypertension. J Hepatol. 2000;32:141-156.
2. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151-1157.
3. Boyer JL, Chatterjee C, Iber FL, et al. Effect of plasma volume expansion on portal hypertension. N Engl J Med. 1966;275:750-755.
4. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilation, plasma volume expansion and the hyperdynamic circulatory state in portal hypertensive rats. Hepatology. 1992;15:323-328.
5. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38:S69-S89.
6. Cereda JM, Roulot D, Braillon A, et al. Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. J Hepatol. 1989;9:246-251.
7. Garcia-Pagan JC, Salmeron JM, Feu F, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology. 1994;19:1095-1099.
8. Sugano S, Kawafure T, Okajima T, et al. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci. 1998;43:893-897.
9. Long RG. Review: long-acting somatostatin analogues. Aliment Pharmacol Ther. 1987;1:191-200.
10. Garcia-Pagan JC, Escorcell A, Moitinho E, et al. Influence of pharmacological agents on portal hemodynamics: Basis for its use in the treatment of portal hypertension. Sem Liv Dis. 1999;19:427-438.
11. Chatila R, Ferayorni L, Groszmann RJ, et al. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology. 2000;31:572-576.
12. Malesci A, Tacconi M, Valentini A, et al. Octreotide long-term treatment in patients with portal hypertension: Persistent inhibition of postprandial glucagon response without major changes in renal function. J Hepatol. 1997;26:816-825.
13. Benoit JN, Zimmerman B, Premen AJ, et al. Role of glucagon in the splanchnic hyperemia of chronic portal hypertension. Am J Physiol. 1986;251:674-677.
14. Pizcueta MP, Casamitjana R, Bosch J, et al. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. Am J Physiol. 1990;258:191-195.
15. Perello A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology. 1999;30: 1393-1397.
16. Iwao T, Toyonaga A, Oho K, et al. Value of Doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension. Am J Gastroenterol. 1997;26:305-311.
17. Taurel P, Blanc P, Dauzat M, et al. Doppler study of mesenteric, hepatic and portal circulation in alcoholic cirrhosis: Relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure. Hepatology. 1998;28:932-936.
18. Iwao T, Oho K, Sakai T, et al. Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepatol. 1998;28:847-855.
19. Albillos A, Perez-Paramo M, Cacho G, et al. Accuracy of portal and foerearm blood flow measurements in the assessment of the portal pressure response to propranolol. J Hepatol. 1997;27:496-504.
20. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23:164-176.
21. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387-395.
22. Bernardi M, Trevisani R, Capelli M, et al. Study of renal function, renin-aldosterone axis and plasma electrolytes during diuretic treatment of patients with cirrhosis of the liver and ascites. Ital J Gastroenterol. 1982;14:199-204.
23. Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 1980;78:92-99.
24. Ballet F, Chretien Y, Rey C, et al. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther. 1988;244:233-235.
25. Segel N, Bayley TJ, Paton A, et al. The effects of synthetic vasopressin and angiotensin on the circulation in cirrhosis of the liver. Clin Sci. 1963;25:43-55.
26. Bataller R, Gines P, Nicolas GM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149-1156.
27. Nishida H, Giostra E, Spahr L, et al. Acute effects of somatostatin, octreotide or placebo in patients with cirrhosis: a double-blind study. Abstr. Hepatology. 1998;28:235.
28. Moller S, Brinch K, Henriksen JH, et al. Effect of octreotide on systemic, central, and splanchnic hemodynamics in cirrhosis. J Hepatol. 1997;26:1026-1033.
29. Yang YY, Lin HC, Huang YT, et al. Adaptive vasodilatory response of octreotide in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2001;281:117-123.
30. Escorsell A, Bandi JC, Andreu V, et al. Desensitization of the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology. 2001;120:161-169.
31. Aguilera G, Parker DS, Gatt KJ. Characterization of somatostatin receptors in rat adrenal glomerulosa zone. Endocrinology. 1982;111:1376-1382.
32. Sieber C, Gnadinger M, del Pozo E, et al. Effect of a new Somatostatin analogue SMS 201-995 (sandostatin) on the reninaldosterone axis. Clin Endocrinol. 1988;28:25-32.
33. Aguilera G, Parker DS, Gatt KJ. Somatostatin modulates effects of angiotensin II in adrenal glomerulosa zone. Nature. 1982;292:262-263.
34. + retention in portal hypertensive rats. Gastroenterology. 1993;104:575-579.
35. Sabat M, Guarner C, Soriano G, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci. 1998;43:2184-2189.
36. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide vs octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005;100:879-885.
37. Pomier-Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: A randomized double-blind, placebo-controlled, crossover study. Hepatology. 2003;38:238-243.
38. Sieber CC, Lee FY, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portal hypertensive rats. Hepatology. 1996;23:1218-1223.